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ABSTRACT
Background: CD157/Bst1 glycoprotein is expressed in >85% of malignant pleural 
mesotheliomas and is a marker of enhanced tumor aggressiveness.
Results: In vitro, mesothelial cells (malignant and non-malignant) released 
CD157 in soluble form or as an exosomal protein. In vivo, sCD157 is released and 
can be measured in pleural effusions by ELISA. Significantly higher levels of effusion 
sCD157 were detected in patients with malignant pleural mesothelioma than in 
patients with non-mesothelioma tumors or with non-malignant conditions. In our 
patient cohort, the area under the receiver-operating characteristic curve for sCD157 
that discriminated malignant pleural mesothelioma from all other causes of pleural 
effusion was 0.685, cut-off (determined by the Youden Index) = 23.66 ng/ml (62.3% 
sensitivity; 73.93% specificity). Using a cut-off that yielded 95.58% specificity, 
measurement of sCD157 in cytology-negative effusions increased sensitivity of 
malignant pleural mesothelioma diagnosis from 34.42% to 49.18%. 
Conclusions: Evaluation of soluble CD157 in pleural effusions provides a 
diagnostic aid in malignant mesothelioma. 
Methods: Soluble CD157 (sCD157) was detected biochemically in culture 
supernatants of malignant and non-malignant mesothelial cells, and in pleural 
effusions from various pathological conditions. An ELISA system was established to 
measure the concentration of sCD157 in fluids, and extended to analyze sCD157 in 
pleural effusions from a cohort of 295 patients.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is an 
incurable tumor that originates from mesothelial cells 
lining the pleural cavity. MPM is associated with asbestos 
exposure and because of its long latency, tumor incidence 
is predicted to increase significantly in the next decade, 
especially in countries where asbestos has not been 
banned [1]. Although Italy banned asbestos in 1992, 
mesothelioma remains a major public health concern due 
to work and general environmental exposure to asbestos, 
especially in the industrial north. Due to its insidious 
onset and delay in clinical detection, MPM is typically 
diagnosed at advanced stages and the overall prognosis 
is poor [2]. Palliative combined platinum and anti-folates 
chemotherapy is considered standard care but gives a 
modest survival advantage of approximately three months, 
compared to cisplatin alone [3]. 
Over 80% of MPM patients present dyspnea with 
malignant pleural effusion [4], caused in part by increased 
vascular permeability and tissue leakage. Pleural fluid 
obtained by thoracentesis often contains malignant cells, 
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and effusion cytology constitutes the most common 
method for establishing a diagnosis. However, in MPM, 
the sensitivity of cytological evaluation is low thus 
histological examination of biopsy specimens obtained by 
thoracoscopy is considered the gold standard diagnostic 
procedure [5, 6]. 
This dismal clinical scenario highlights the urgent 
need for more sensitive and non-invasive tools to aid the 
diagnostic workflow. In this setting, tumor biomarkers 
can play a meaningful role in diagnosis and prognosis, 
in predicting and monitoring treatment responses, and in 
screening for early detection of disease [7]. 
CD157/Bst1 is a cell-adhesion glycoprotein encoded 
by the human bone marrow stromal cell 1 (BST1) gene, 
which maps to 4p15.32 [8] and belongs to the ADP-ribosyl 
cyclase gene family [9, 10]. In addition to the canonical 
protein of 318 amino acids, a second CD157 proteoform of 
333 amino acids has been recently identified [11]. The two 
proteins share similar distribution and functions, but only 
the canonical form displays NAD glycohydrolase activity. 
CD157 exists both as glycosylphosphatidylinositol (GPI)-
anchored membrane protein implicated in the control 
of leukocyte trafficking [12], and as a soluble protein 
whose biological role is as yet unknown [13]. CD157 
is highly expressed in monocytes, polymorphonuclear 
leukocytes (PMN) [14] and in more immature myeloid 
stages [15], and also in vascular endothelial cells [16] 
and bone marrow stromal cells [17]. CD157 is also 
expressed in 97% of acute myeloid leukemia patients and 
is currently under investigation as a potential candidate 
for antibody-based targeted therapy [18]. CD157 regulates 
cell adhesion and migration by high affinity binding to 
selected components of the extracellular matrix within 
their heparin binding domains [19].
Over the past decade, we have established a link 
between CD157 expression and prognosis in certain 
solid tumors [20, 21]. CD157 is expressed in >90% of 
epithelial ovarian cancers where high CD157 expression 
correlates with increased tumor aggressiveness, promotes 
epithelial-to-mesenchymal transition [22] and is an 
independent prognostic factor for overall survival [23]. 
CD157 is also expressed in >85% of MPM, and again, 
high CD157 expression is associated with enhanced tumor 
aggressiveness and with reduced sensitivity to platinum-
based chemotherapy, notably in the biphasic histotype 
[24]. The combination of CD157 expression in MPM and 
the knowledge that a soluble form of the protein has been 
detected in serum of patients with autoimmune disorders 
[13] suggested we examine pleural fluid in MPM for 
the presence of soluble CD157 (sCD157). In this study, 
first we explored the ability of MPM cells to produce 
sCD157 in vitro, and then we investigated the presence 
of sCD157 in pleural effusions. Finally, we performed a 
first assessment of the potential clinical utility of sCD157 
in MPM patients.
RESULTS
Pleural mesothelium-derived cell lines release 
CD157 in cell culture supernatants
To assess the ability of cells of mesothelial origin 
to shed CD157 in culture supernatants, we selected 
the following cell lines: (i) Met-5A, a non-malignant 
mesothelial cell line, CD157-positive; (ii) CG98, MMP, 
MPP89, and MM98 mesothelioma, CD157-positive; and 
(iii) MSTO-211H and REN mesothelioma, CD157-negative 
cell lines. The CD157 expression status for each cell line 
was confirmed by flow cytometry (Figure 1A, 1C). 
Cells were maintained in serum-free medium for 
48 hours, then culture media and cells were collected 
separately for western blot analysis. CD157 was detected 
in supernatants from Met-5A cells (Figure 1B) and from 
the CD157-positive MPM cell lines (but not in supernatants 
from the two CD157-negative MPM cell lines) (Figure 1D). 
By western blotting, we observed the typical 45–50 kDa 
smear, a characteristic feature shared with membrane-bound 
CD157 (Figure 1D) due to heterogeneous glycosylation 
[25]. Thus, soluble forms of CD157 are released in vitro 
by non-malignant and malignant mesothelial cells, and 
these forms are recognized by the same SY/11B5 mAb that 
detects membrane-bound CD157. 
Next, we set up a double determinant ELISA 
to measure the concentration of sCD157 in culture 
supernatants from our mesothelial cell panel. The assay 
confirmed that all CD157-positive cells released sCD157 
into the culture medium, in variable amounts depending 
on the cell line. As expected, sCD157 was not detected 
in supernatants from CD157-negative cells (MSTO-211H 
and REN) (Figure 1E). As CG98 MPM cells released the 
most sCD157, they were used to investigate the kinetics of 
sCD157 accumulation in vitro. Using sub-confluent CG98 
cell culture medium, sCD157 was detected within 2 hours 
of serum removal, and continued to increase up to 48 hours 
(Figure 1F, 1G). Beyond this timeframe, the viability of 
serum-deprived cells was compromised, preventing further 
analysis.
GPI-anchored CD157 is found in detergent-resistant 
microdomains [26] and may be secreted via exosomes 
[27, 28]. To assess this possibility, culture medium was 
obtained from Met-5A (mesothelial cells, CD157-positive) 
and CG98 (MPM, CD157-positive) and ultracentrifuged 
to obtain the microvesicle pellet. By western blotting, we 
detected CD157 in the pellet from both Met-5A and CG98 
cell supernatants (Figure 2A, 2B). Sucrose density gradient 
fractionation of the CG98 microvesicle pellet then showed 
that CD157-positive vesicles were included in the low-
density sucrose fractions enriched in exosomes (Figure 2C), 
as confirmed by coexpression of CD81, a tetraspanin 
protein considered a prototypic exosome marker [29, 30]. 
These findings demonstrate that, in vitro, CD157 is at least 
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Figure 1: Analysis of CD157 expression and release in malignant and non-malignant mesothelial cell lines.  Flow 
cytometric analysis of CD157 expression in (A) Met-5A non-malignant mesothelial cells and (C) six MPM cell lines. In each sample, 
104 cells were analysed; x-axis = fluorescence intensity, y-axis = number of cells (events). White histograms represent the expression of 
membrane CD157 in live cells analysed by the SY/11B5 mAb, shaded histograms indicate isotype-matched control mAb. Western blot 
analysis of CD157 in (B) Met-5A cells and (D) six MPM cell lines maintained in serum-free culture medium for 48 hours. Proteins were 
separated by SDS-PAGE in non-reducing conditions, blotted and probed with the SY/11B5 anti-CD157 mAb; β-Actin was used as a loading 
control of the total lysates. One representative experiment is shown (n = 3). (E) sCD157 was measured by the double determinant ELISA 
described in Materials and Methods, in serum-free culture medium of the indicated cell lines. Results are expressed as ng/ml of soluble 
CD157 and histograms represent the mean ± s.e.m. of three experiments performed in duplicate. (F) Western blot time-course analysis of 
sCD157 accumulated in serum-free culture medium of CG98 MPM cells. Proteins were precipitated by TCA, separated by SDS-PAGE in 
non-reducing conditions, transferred to PVDF membrane and probed with the SY/11B5 anti-CD157 mAb. One representative experiment 
is shown (n = 2). (G) Quantification of sCD157 concentration by the double-determinant ELISA in serum-free culture medium of CG98 
MPM cells at the indicated time points. Results are expressed as ng/ml of soluble CD157. Histograms represent the mean value ± s.e.m. of 
three experiments performed in duplicate. 
Oncotarget22788www.oncotarget.com
partly released in the form of exosome-bound protein both 
by benign and malignant mesothelial cells.
Identification of CD157 in pleural effusions
We then investigated the possible release of sCD157 
by mesothelial cells in vivo and its eventual presence in 
pleural effusions. There are many causes of fluid build-
up in the pleural cavity, from lung infections, heart 
failure, to primary and metastatic cancers. Therefore, we 
measured the sCD157 content in twelve representative 
pleural effusions of diverse pathological origin: 6 MPM, 
3 lung cancer and 3 non-cancerous (1 pleurisy, 2 chronic 
inflammation). Soluble CD157 was detected by ELISA 
in all 12 effusion samples, in varying concentrations 
(Figure 3A), confirming that sCD157 is released and 
measurable in pleural effusions. 
Effusions were also analysed to establish if we 
were also detecting CD157-positive exosomes. Exosomes 
were isolated from the same 12 effusions analysed above, 
exploiting a procedure (Total Exosome Isolation Kit) that 
efficiently isolates intact exosomes from small amounts of 
effusion [31]. Western blot analysis detected both CD157 
and the exosome marker CD81 in all effusions (Figure 
3B). We then focused on exosomes derived from the MPM 
patients, and had sufficient amounts of pleural effusion 
from 4 of the 6 MPM samples (nos. 1, 2, 4 and 6) for 
sucrose density gradient fractionation which confirmed 
the presence of CD157-positive MPM exosomes. Indeed, 
in the 4 samples, sCD157 was mainly detected in the 
low-density sucrose fractions (Figure 3C) containing the 
CD81-positive exosomes (Figure 3D). 
Quantification of soluble CD157 levels in pleural 
effusions
Next, to investigate the potential clinical utility of 
sCD157 as a biomarker in MPM patients, we retrospectively 
measured sCD157 concentration in pleural effusions 
obtained from 295 consecutive patients of whom 61 
(20.67%, 40 male/21 female) were diagnosed with MPM, 
129 had non-MPM malignancies, and 105 had effusions of 
Figure 2: Analysis of CD157 expression in vesicles released by mesothelial cells. Western blot analysis of CD157 expressed 
in total cell lysate (30 µg/lane), cell culture medium (1 ml, TCA precipitated) and vesicles (30 µg/lane) from (A) non-malignant Met-5A 
mesothelial cells or (B) CG98 mesothelioma cells, detected by SY/11B5 mAb. A representative experiment is shown (n = 3). (C) Western 
blot analysis of CD157 and CD81 expression in exosomes obtained from serum-free culture medium of CG98 cells by sucrose density 
gradient fractionation. Twelve fractions were collected from the top of the gradient, proteins from each fraction were precipitated with 
methanol/chloroform, separated by 10% SDS-PAGE, transferred to PVDF membranes and immunoblotted with anti-CD157 or anti-CD81 
mAb. A representative experiment is shown (n = 3).
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non-neoplastic origin (Table 1). For 21 of the MPM patients, 
the diagnosis was based on effusion cytology and confirmed 
by immunohistochemistry of biopsy specimen. For 33 
MPM, effusion cytology was inconclusive so diagnosis 
was made by immunohistochemistry of biopsy specimens. 
For 7 MPM patients, thoracoscopy was not possible and 
diagnosis was based on effusion cytology with support from 
the clinicopathological and radiographic findings. For the 
latter, the histological subtype could not be defined whereas 
among the other MPM, 47 (77.05%) were epithelioid, two 
(3.28%) were biphasic and five were (8.2%) sarcomatoid. 
Of the 129 patients with non-MPM malignancy (43.73%, 76 
male/53 female), 82 had lung cancer and 47 had cancer of 
non-pulmonary origin. In 105 patients (35.6%, 66 male/39 
female) effusions were due to non-malignant thoracic 
disorders, including pleurisy, chronic inflammation, heart 
failure, trauma, tuberculosis, pneumothorax and effusions 
of unspecified origin. There was no significant difference 
in age between the groups (for patient characteristics, see 
Table 1).
Soluble CD157 was measured in all 295 pleural 
effusions. MPM effusions had significantly higher 
Figure 3: Identification of soluble CD157 in pleural effusions. (A) Detection of sCD157 in pleural effusions from patients 
with different malignant and non-malignant thoracic diseases, measured by the double determinant ELISA. Results are expressed as 
ng/ml of soluble CD157, and histograms are the mean value ± s.e.m. of three independent experiments performed in duplicate. (B) 
Representative western blot analysis of CD157 and CD81 expressed by exosomes purified using the Total Exosomes Isolation kit from 
200 µl of pleural effusion from patients with MPM (6), lung cancer (3) or non-malignant thoracic pathologies (3). Exosome preparations 
were separated by SDS-PAGE, transferred to PVDF membrane and probed with anti-CD157 or anti-CD81 mAb. (C) and (D) Vesicles were 
purified by ultracentrifugation of pleural effusions from four MPM patients and subjected to sucrose density gradient fractionation. Twelve 
fractions were collected from the top of the gradient, proteins from each fraction were precipitated with methanol/chloroform, separated by 
10% SDS-PAGE, transferred to PVDF membranes and immunoblotted with (C) anti-CD157 or (D) anti-CD81 mAb. One representative 
experiment is shown (n = 2).
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concentrations of sCD157 than those from patients 
with either non-MPM malignancies [regardless of their 
lung (P < 0.0001) or non-lung origin (P = 0.00049)] 
or non-malignant diseases (P < 0.0001). The effusion 
concentration of sCD157 in patients with non-MPM 
malignancies or with non-malignant diseases were 
comparable (Figure 4A) (Table 1). 
When we compared MPM effusions (61) versus all 
non-MPM effusions (234), sCD157 concentration was 
significantly higher in MPM patients (P < 0.0001) (Figure 
4B) and not influenced by patient age or gender (data not 
shown). A ROC curve was generated to assess the ability 
of sCD157 concentration in pleural effusions to distinguish 
between MPM patients and all other patients in this study: 
the AUC for sCD157 was 0.685 (95% CI = 0.599–0.771) 
(Figure 4C). Using the maximum value of the Youden 
Index, the sCD157 cut-off point was 23.66 ng/ml. 
At a threshold of 23.66 ng/ml, sCD157 sensitivity was 
62.3% and specificity was 73.93%. 
In further ROC analyses, MPM effusions yielded an 
AUC of 0.697 (95% CI = 0.606–0.789; P < 0.0001) versus 
lung cancer effusions, an AUC of 0.657 (95% CI = 0.554–
0.761; P = 0.0052) versus non-lung cancer effusions, and 
an AUC of 0.688 (95% CI = 0.596–0.779; P < 0.0001) 
versus non-malignant effusions. In conclusion, sCD157 
levels were significantly higher in MPM effusions than in 
Table 1: Patients characteristics and sCD157 levels in pleural effusions in each group
Diagnosis Gender (M/F)
Median age, 
years (range)
Number 
of cases (%)
sCD157 (ng/ml)
median (IQR) P value
**
Pleural effusions (n = 295)
MPM  (n = 61) 40/21 76 (52–94) 31.02 (17.97–51.51) ref
Epithelial 47 (77.05)
Biphasic 2 (3.28)
Sarcomatoid 5 (8.20)
NOS* 7 (11.48)
Non-MPM metastatic cancers 
(n = 129)
Lung cancer (n = 82) 56/26 73 (33–93) 18.71 (11.12–23.7) <0.0001
Non-small cell 16 (19.51)
Adenocarcinoma 42 (51.22)
Squamous cell 4 (4.88)
Unknown histotype 20 (24.34)
Other cancers (n = 47) 20/27 76 (20–94) 19.8 (10.53–31.25) 0.0049
Breast 11 (23.40)
Lymphoma 8 (17.02)
Colorectal 5 (10.64)
Leukemia 4 (8.51)
Ovary 3 (6.38)
Renal 3 (6.38)
Hepatocellular 2 (4.26)
Pleural 2 (4.26)
Gastric 1 (2.13)
Pancreatic 1 (2.13)
Sarcoma 1 (2.13)
Peritoneum 1 (2.13)
Unknown primary 5 (10.64)
Non-malignant diseases
(n = 105) 66/39 79 (24–95) 18.6 (11.70-24.10) <0.0001
*Not otherwise specified. 
**P value between indicated groups and the MPM group as the reference(ref).
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Figure 4: Quantification of sCD157 levels in pleural effusions. sCD157 was measured by the double determinant ELISA in 295 
pleural effusions, and the levels of sCD157 in pleural effusions from patients with MPM (n = 61) were compared with (A) other metastatic 
cancers of lung (n = 82) or non-lung (n = 47) origin, or with non-malignant pathologies (n = 105). (B) sCD157 levels in pleural effusions 
from patients with MPM (n = 61) were compared with all pleural effusions from patients with non-MPM conditions (n = 234). Each data 
point corresponds to sCD157 concentration of a single effusion sample, and represents the mean value of three independent experiments 
performed in duplicate. Boxes indicate the range (25th-75th percentiles), whiskers indicate major and minor values; the horizontal line 
within the boxes indicates the median sCD157 concentration of each group. (Mann–Whitney U-test, ****P < 0.0001; ***P = 0.00049; 
ns = not significant). (C) The optimal cut-off for discriminating MPM from all other thoracic diseases was determined by receiver operating 
characteristic (ROC) curve analyses of the area under the ROC curve (AUC) for MPM patients versus non-MPM patients (AUC = 0.685; 
95% CI = 0.599–0.771, sensitivity = 62.3% and specificity = 73.93%). Horizontal dashed line indicates the cut-off determined by the 
Youden Index (sCD157 = 23.66 ng/ml). 
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other types of pleural effusion. However, sCD157 alone 
does not reach sufficient sensitivity and specificity as 
diagnostic marker to discriminate all patients with MPM 
from the other patient groups.
Soluble CD157 aids cytological diagnosis of 
MPM
Although not diagnostic per se, sCD157 could 
contribute to the cytological diagnosis of MPM. To 
explore this possibility, the 75th percentile (sCD157 = 
51.51 ng/ml) was chosen as cut-off point to minimize the 
probability of a false-positive result. This cut-off yielded 
96.58% specificity for MPM effusions versus all other 
effusions, regardless of their origin. In order to compare 
sCD157 concentration with the cytological diagnosis 
performed on all 295 pleural effusions, the cytopathology 
reports were reviewed. These revealed that 162 (55%) 
pleural effusions were classified as cytology-negative, 38 
(13%) as suspicious of malignancy or containing atypical 
mesothelial cells, 74 (25%) were diagnosed as non-MPM 
tumors, and 21 (7%) as MPM. 
In the cytology-negative group, high sCD157 (≥51.51 
ng/ml) was detected in 9/162 (5.55%) effusions. Of this 
cytology-negative/high sCD157 group: 3/9 were diagnosed 
as MPM based on the biopsy specimens (Figure 5); 2/9 were 
patients with a previous diagnosis of cancer (Hodgkin’s 
lymphoma, sarcomatoid kidney carcinoma), and 4/9 were 
from patients with non-malignant diseases [pleurisy (1), 
tuberculosis (1) and chronic inflammation with elevated 
PMN (2)]. Of 38 pleural effusions classified as suspicious of 
malignancy, 6 (15.79%) had sCD157 levels ≥51.51 ng/ml, 
and all 6 were effusions from MPM patients (Figure 5). In 
conclusion, by using the same pleural effusion sample to 
measure sCD157 and to evaluate cytology, we were able to 
make a diagnosis of mesothelioma in 30/61 MPM patients 
in our cohort, raising the sensitivity of effusion-based 
MPM diagnosis from 34.42% (cytology alone) to 49.18% 
(cytology + sCD157).
Analysis of MPM patients with high and low 
sCD157 levels in pleural effusion
When the levels of sCD157 were compared in 
pleural effusions from patients with MPM of different 
histological type, no significant differences were observed 
(Figure 6A). However, due to the small number of patients 
with sarcomatoid and biphasic mesothelioma, this finding 
requires further analysis. Levels of sCD157 do not 
appear to be significantly influenced by the presence of 
malignant or atypical mesothelial cells in pleural effusions 
(Figure 6B) or by the presence of PMN (Table 2).
Next we asked if there was a correlation between 
sCD157 levels in MPM effusions and CD157 expression 
in the primary tumor. We had 29 MPM biopsies for which 
residual specimens were available, and they were stained for 
CD157 by immunohistochemistry. CD157 was expressed in 
all 29 biopsy specimens examined at variable levels (median 
H-score = 110,  IQR: 75–165) and with different (membrane/
cytoplasmic) distribution patterns, as previously described 
[24]. When these patients were dichotomized according 
to the median sCD157 effusion concentration of the entire 
cohort (31.02 ng/ml, Table 1), 15 biopsies (51.72%) were 
from MPM patients with high sCD157 (≥31.02 ng/ml) in the 
corresponding effusion, and 14 (48.28%) from patients with 
low sCD157 (<31.02 ng/ml). 
Next, tissue samples were grouped according to the 
median CD157 H-score to assess the relationship between 
CD157 expressed by the tumor and sCD157 in the effusion. 
Results showed a trend towards an association between 
CD157 staining and sCD157 in effusion of the same patient: 
12/18 (66.67%) biopsies with a CD157 H-score ≥110 had 
high sCD157 concentrations in the corresponding pleural 
effusion compared to only 3/11 (16.67%) of those with a 
CD157 H-score < 110 (P = 0.06, Table 2).
At 1-year follow-up, data were available for 54 of 
the MPM patients in our cohort. At the time of testing, 
27 patients had high effusion sCD157 (≥31.02 ng/ml) and 
27 had low effusion sCD157 (<31.02 ng/ml). By the end 
of the observation period, 43 patients had died (median 
survival was 7 months) and 11 patients remained alive 
(median survival was 16 months). Of note, 26 of the 27 
high sCD157 patients died of MPM in the follow-up 
period whereas only 17 of the 27 low sCD157 patients 
died (P = 0.005, Table 2). 
Soluble CD157 levels in pleural effusion and 
MPM patient survival
To test the possibility that sCD157 could be a 
prognostic marker, patients with MPM were grouped 
according to the median sCD157 concentration in 
effusions (31.02 ng/ml). The median survival of high 
sCD157 patients (≥31.02 ng/ml) was 10 months (95% CI = 
1.519–18.481), while for low sCD157 patients the median 
survival was 16 months (95% CI = 6.654-25.346). 
Survival data for MPM patients with high sCD157 
were plotted against survival data for patients with low 
sCD157 and tested for significant difference using the 
Kaplan-Meier method. Although the median survival 
was reduced in high sCD157 patients compared to low 
sCD157 patients, the difference in OS was not statistically 
significant (P = 0.574, log-rank), indicating that sCD157 
effusion concentrations before diagnosis or at time of 
diagnosis was not a significant predictor of survival in 
MPM patients in this study. 
DISCUSSION
This study shows that CD157 is released in vitro 
both by malignant and non-malignant mesothelial cells 
and demonstrates the feasibility of measuring sCD157 
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in vivo in pleural effusions. Soluble CD157 levels are 
significantly higher in pleural effusions from MPM 
patients than in those from all other patient groups studied 
here. CD157 can be shed either as a soluble protein, 
generated by proteolytic cleavage of the membrane-bound 
protein, or as an exosome-anchored protein. Although not 
specific for MPM, exosomal CD157 has recently been 
identified among proteins that define a unique exosome-
related signature in mesothelioma cell lines [32]. In view 
of CD157’s  pivotal role in cell-matrix interaction [19], it 
is tempting to speculate that exosomal CD157 in pleural 
effusions has the potential to participate to the cross-talk 
between tumor cells and the surrounding environment, 
thus influencing tumor behavior. In particular, MPM-
derived exosomes have been shown to regulate cell 
adhesion and migration in vitro [33], both functions in 
which CD157 has a leading role in MPM [24] and ovarian 
cancer [23]. 
Pleural effusions form not only in MPM patients 
but also in other types of cancer and in a number of non-
malignant pathologies. Thus, cytological examination 
is routinely adopted as the most common and safe 
diagnostic method to discriminate between malignant 
and non-malignant effusions. Nevertheless, despite high 
specificity, cytology often provides false negative results, 
even in repeated samplings, meaning that a positive result 
is informative, but a negative one is not. Moreover, there is 
a general consensus that the phenotypic discrimination of 
malignant mesothelial cells from non-malignant reactive 
cells is difficult, as is the distinction of MPM from 
other tumors, especially adenocarcinoma [34]. For these 
reasons, cytology is able to diagnose pleural metastases 
in 60–90% of tumors, but in only 30–40% of MPM 
[35] with higher sensitivity for epithelioid compared to 
sarcomatoid histotype [36]. Hence, the measurement 
of tumor markers in pleural effusions may represent 
a complementary tool for the diagnosis of MPM, or an 
alternative to thoracoscopy in subjects unfit for such an 
invasive procedure [37]. However, currently available 
markers offer insufficient sensitivity and specificity and 
are not used in clinical practice to diagnose MPM [38, 39]. 
Having detected sCD157 in pleural effusions, we 
explored its potential usefulness as a diagnostic tool. In our 
retrospective case series, sCD157 levels were significantly 
higher in MPM effusions than in all other pleural effusions, 
both non-MPM malignant and non-malignant. Instead, 
Figure 5: Contribution of sCD157 to the cytological diagnosis of MPM. sCD157 concentrations in pleural effusions were 
plotted against the diagnosis established by cytopathology. Each data point indicates mean concentration of sCD157 of a single effusion 
sample and represents the mean value of three independent experiments performed in duplicate. Horizontal dashed line indicates the cut-off 
corresponding to the 75th percentile (sCD157 = 51.51 ng/ml). Boxes indicate the range (25th–75th percentiles), whiskers indicate major 
and minor values; the horizontal line within the boxes indicates the median sCD157 concentration of each group. Red dots highlight nine 
effusions from MPM patients with sCD157 ≥51.51 ng/ml, not diagnosed by cytology.
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sCD157 levels were comparable in non-MPM malignant 
and non-malignant effusions, indicating that sCD157 is 
not a general marker of malignancy. Soluble CD157 was 
above the cut-off value of 23.66 ng/ml, indicating the best 
combination of sensitivity and specificity, in over 62% of 
effusions from MPM obtained before diagnosis of MPM 
was established, regardless the histological type and the 
identification of malignant or atypical mesothelial cells. 
Combined analysis of effusion sCD157 and biopsy CD157 
from the same patient showed that higher levels of sCD157 
tend to correlate with stronger immunohistochemical 
staining for CD157, suggesting that sCD157 derived at least 
Figure 6: Analysis of MPM patients with high and low sCD157 levels in pleural effusion. Quantification by the double 
determinant ELISA of sCD157 in pleural effusions from patients with MPM grouped in panel (A) according to the epithelioid, biphasic, 
sarcomatoid or NOS (not otherwise specified) histotype, and in panel (B) according to the presence or absence of neoplastic or atypical 
mesothelial cells. Each data point corresponds to sCD157 concentration of a single effusion sample, and represents the mean value of three 
independent experiments performed in duplicate. Boxes indicate the range (25th–75th percentiles), whiskers indicate major and minor 
values; the horizontal line within the boxes indicates the median sCD157 concentration of each group.
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in part from the tumor. We noted that four MPM effusions 
were virtually sCD157-negative, so it would seem that the 
absence of measurable amounts of sCD157 does not rule 
out the presence of MPM. Unfortunately, we could not test 
the biopsies from these four patients for CD157 expression 
as no material was available. 
Why some MPM patients show little sCD157 in 
pleural effusions is currently under investigation. The 
finding that 26% of non-MPM malignant or non-malignant 
effusions had high sCD157 can probably be attributed, on 
the one hand, to expression of CD157 in certain tumors, 
such as peritoneal and ovarian cancers [23] (while no 
information on CD157 expression in breast cancer, lung 
cancer, kidney cancer and Hodgkin’s lymphoma is so far 
available) and on the other, to the accumulation of proteases 
in effusions accompanying severe chronic inflammatory 
disorders. These proteases can cleave CD157 expressed 
in the stromal, endothelial [40] and inflammatory cells 
that form the microenvironment. Although the presence of 
PMN apparently does not influence the sCD157 levels in 
MPM effusions in our cohort, it is possible that in selected 
pathological contexts, inflammatory cells may release 
Table 2: Clinical and pathological characteristics of MPM patients and their association with sCD157 concentration 
in pleural effusions
Cases sCD157 <31.02 ng/ml sCD157  ≥31.02 ng/ml P value*
MPM, n 61 30 31
Age at diagnosis, y 0.062
mean ± SD 73.07 ± 10,46 77.39 ± 6.76
median (range) 73.50 (52–94) 79.00 (61–89)
Sex 0.106
Male 40 23 17
Female 21 7 14
Histologic subtype 0.951
Epithelioid 47 23 24
Sarcomatoid 5 3 2
Biphasic 2 1 1
NOSa 7 3 4
Cytology 0.359
negative 21 13 8
positive 21 9 12
suspicious 19 8 11
PMNb (n = 54) 0.516
<10 cells × 10 (HPF, 200×)c 36 17 19
10–50 cells × 1 (HPF, 200×) 14 8 6
>50 cells × 10 (HPF, 200×) 4 1 3
CD157 expression in biopsy tissues (n = 29) 0.06
H-score <110 11 8 3
H-score ≥110 18 6 12
Follow-up (n = 54) 0.005
DODd 43 17 26
AWDe 11 10 1
*P values were determined using the Mann–Whitney U-test for independent samples, the two-sided χ2 or Fisher exact tests. 
aNOS = Not otherwise specified. 
bPMN = polymorphonuclear leukocytes. 
cHPF = High Power Field, microscopy magnification 200×.
dDOD = died of disease.
eAWD = alive with disease.
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CD157. Indeed, high sCD157 was reported in sera from 
patients with rheumatoid arthritis, which is characterized by 
severe systemic chronic inflammatory conditions [13], and 
we also found high levels of sCD157 in two non-malignant 
effusions with elevated numbers of PMN. 
Collectively, our data indicate that although sCD157 
alone does not have the required accuracy for diagnostic 
purposes, measurement of effusion sCD157 can provide 
supporting evidence for diagnosing MPM in symptomatic 
individuals when cytology is inconclusive. Indeed, at 
95.58% specificity, sCD157 evaluation in pleural effusions 
established a diagnosis of MPM in a subgroup of patients 
(9/40) undiagnosed by cytology (regardless of histotype), 
raising the sensitivity of effusion-based diagnosis of MPM 
from 34.42% (obtained by cytology) to 49.18%. Measuring 
sCD157 levels in pleural effusions is convenient as most 
patients routinely undergo thoracentesis to establish the 
nature of the effusion. Soluble CD157 can be assayed in 
stored samples, which allows clinicians to retrospectively 
request the test should cytology fail to establish a diagnosis.
Other biomarkers have been proposed for indirect 
diagnosis of MPM by pleural effusion, including 
mesothelin [41, 42] (the only biomarker approved by 
FDA as a humanitarian use device [43]), osteopontin 
[44], megakaryocyte potentiating factor (an alternative 
cleavage product of the mesothelin precursor protein) [45] 
and fibulin-3 [46], among others [47]. However, despite 
promising early results, none of these markers alone proved 
to have sufficient accuracy for MPM diagnosis [2, 48]. The 
inherent heterogeneity of MPM, emphasized by remarkable 
differences in phenotype and biological features among 
the various MPM subtypes [49], together with the lack of 
distinctive gene expression signatures [50] and key driver 
mutations [51, 52] make it unlikely that an ideal diagnostic 
biomarker for MPM will be found. Rather, it is plausible 
that combined analysis of a panel of biomarkers may 
be the right approach to ameliorate the clinical utility of 
effusion-based MPM diagnosis. This approach could have 
the advantage of shortening the time required for diagnosis 
and reduce the number of patients undergoing invasive 
procedures with the associated risks and costs. The next 
challenge will be to elucidate how to integrate dependable 
markers into effective diagnostic algorithms. 
Our data indicate that, in this study, evaluation of 
sCD157 did not provide prognostic information for patients 
with MPM, even though the median survival of high sCD157 
MPM patients (at diagnosis) was shorter than those of low 
sCD157 patients. Nevertheless, this result requires  careful 
interpretation considering the small number of patients 
examined, and bearing in mind that the biphasic histotype, in 
which CD157 expression levels and prognosis are correlated 
[24] are under-represented in the analyzed case series.
This study was performed in a cohort of MPM 
patients from Northern Italy, which is considered a high-
risk geographic area for mesothelioma because of asbestos 
mining and manufacturing in the past, before the ban came 
into effect [53]. We showed that detection of high levels of 
sCD157 may contribute to the diagnosis of an individual at 
risk of mesothelioma who presents with a pleural effusion 
unsuitable for the cytological diagnosis. However, for CD157 
to confirm its potential clinical utility, independent diagnostic 
validations with separate geographic cohorts, representative 
of all mesothelioma histological types, should be performed. 
In addition, the potential usefulness of sCD157 as ‘risk 
factor’, or as marker of early diagnosis, should be evaluated 
in asbestos-exposed patients with benign effusions, which 
will require a prospective study. Another key step would be 
the combined evaluation of sCD157 and mesothelin in an 
attempt to improve diagnostics for all types of mesothelioma. 
It is noteworthy that 60% of effusions from sarcomatous 
mesothelioma showed high sCD157 concentrations, while 
mesothelin proved to be a useful marker for epithelioid 
mesothelioma but not for other histological variants [41, 42]. 
A concomitant analysis of the best-performing and reliable 
markers for virtually all mesothelioma histotypes may be the 
best approach to improve diagnosis and early detection of 
MPM in the near future.
MATERIALS AND METHODS
Cell lines
Met-5A non-malignant, SV40-immortalized pleural 
mesothelial cells were purchased from American Type 
Culture Collection (ATCC, Manassas, VA). MPP89 and 
MSTO-211H mesothelioma cells were obtained from 
Interlab Cell Line Collection (Advanced Biotechnology 
Center, Genova, Italy). REN and MPP cells were kindly 
provided by L. Moro (University of Novara, Italy) 
who received the cells from S. Albelda (University of 
Pennsylvania, Philadelphia, USA). CG98 and MM98 
MPM cells were obtained from the mesothelioma bio-
bank at the Pathology Unit, City Hospital of Alessandria, 
Italy [54]. All cells were thawed from early-passage frozen 
stocks and were passaged less than six times prior to use. 
Cells were regularly examined for absence of Mycoplasma 
contamination by a PCR-based assay.
Immunofluorescence and flow cytometry
Cells (2 × 105) were incubated for 30 min at 4° C 
with SY/11B5 anti-CD157 mAb (5 μg/ml) [23], washed 
and incubated for 30 min at 4° C with F(ab')2-goat-anti-
mouse IgG-FITC (Jackson ImmunoResearch, DBA, 
Milano, Italy). Flow cytometry was carried out using a 
BD FACS Canto I (BD Biosciences, Milano, Italy) and 
analysed by FlowJo® software. 
Western blot analysis
MPM cells were grown to 80% confluence in 
culture medium containing 10% fetal calf serum (FCS), 
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then maintained in FCS-free conditions. At the indicated 
time, both cells and culture medium were collected and 
processed. The culture medium was centrifuged for 
10 min at 300 × g and 20 min at 10,000 × g, to remove 
residual cells and debris. Proteins were precipitated with 
trichloroacetic acid (TCA), washed twice with acetone, air-
dried and dissolved in 2× non-reducing SDS sample buffer 
(30% sucrose, 80 mM Tris-HCl pH 8.8, 3% SDS, 0.01 
mg/ml bromophenol blue). Total lysates were obtained 
in ice-cold RIPA lysis buffer supplemented with protease 
inhibitor cocktail (Sigma-Aldrich). Protein concentration 
was determined by the Quick Start Bradford protein assay 
(Bio-Rad, Milano, Italy) using bovine serum albumin as 
standard. Equal amounts of proteins (30 μg/lane) were 
separated by SDS-PAGE, transferred to polyvinylidene 
difluoride (PVDF) membranes, blocked with 5% milk, 
and probed with the indicated primary antibody, followed 
by horseradish peroxidase (HRP)-conjugated goat-anti-
mouse polyclonal antibody and HRP-conjugated anti-
β-Actin antibody (Santa Cruz Biotechnologies, Milano, 
Italy). Immunoreactive bands were visualized by Westar 
ECL substrate (Bio-Rad). Images were captured with a 
ChemiDoc™ XRS+ System.
Isolation of microvesicles and exosomes from cell 
culture medium
Vesicles were isolated from culture medium of cells 
maintained in FCS-free medium for the indicated time, as 
described [55]. FCS-free culture medium was collected 
and centrifuged for 10 min at 300 × g to remove residual 
cells, then supernatants were centrifuged for 20 min at 
2,000 × g and for 30 min at 10,000 × g, to remove debris. 
Membrane vesicles were centrifuged at 100,000 × g for 
2 h, washed in PBS, and ultracentrifuged at 100,000 × g 
for 1 h. For Western blotting, vesicles were suspended in 
RIPA buffer and quantified using the Bradford method. 
Equal amounts of protein were boiled with non-reducing 
SDS-sample buffer and further processed. 
To isolate exosomes, vesicles were suspended in 
0.25 M sucrose in TBS and loaded onto a 5-step gradient 
comprising layers of 2, 1.3, 1.16, 0.8 and 0.5 M sucrose 
in TBS, as described [56] and centrifuged at 100,000 × g 
for 2.5 h. Twelve fractions (400 μl/each) were collected 
from the top of the gradient and proteins in each fraction 
were precipitated with methanol/chloroform and analyzed 
by SDS-PAGE and Western blot.
Isolation of exosomes from pleural effusions
Exosomes from pleural effusions were isolated 
using the Total Exosomes Isolation kit (Life Technologies, 
Monza, Italy) following the manufacturer’s instructions. 
Briefly, 200 µl of pleural effusion were centrifuged at 
2,000 × g, at room temperature for 30 min to remove 
cells and debris. Then the appropriate amount of Total 
Exosomes Isolation reagent was added, according to 
the manufacturer’s recommendations. Mixtures were 
vortexed and incubated at room temperature for 30 min 
before centrifugation at 10,000 × g for 10 min to collect 
exosomes. Pellets containing exosomes were suspended 
in RIPA buffer and quantified using the Bradford method. 
Selected effusion samples were processed for exosome 
purification by sucrose density gradient, as described 
above, and analyzed by SDS-PAGE and Western blot. 
Enzyme-linked immunosorbent assay (ELISA)
sCD157 levels were quantified in ng/ml using a 
double determinant ELISA. MaxiSorp microtiter plates 
(Nunc, Roskilde, Denmark) were coated overnight at 4° C 
with 5 μg/ml of SY/11B5 anti-CD157 mAb in PBS. After 
blocking with Pierce™ Protein-Free T20 Blocking Buffer 
(PFBB-T, Pierce, Thermo Fisher Scientific, Milano, 
Italy) for 2 h at room temperature, samples (100 µl/well) 
were added and incubated overnight at 4° C. Cell culture 
medium was used undiluted and pleural effusions were 
diluted 1:50 in PFBB-T. All samples were analysed in 
duplicate in at least three independent tests. After four 
washes with PFBB-T (300 µl/well), 0.5 μg/ml of rabbit 
polyclonal IgG to human CD157 (Sigma-Aldrich) were 
added for 2 h at room temperature. After four washes with 
PFBB-T, plates were incubated for 1 h at 37° C with HRP-
conjugated anti-rabbit IgG (1:5,000 in PFBB-T). After 
extensive washing, the reaction was developed with 100 μl 
of tetramethylbenzidine (TMB; BioFX, Milano, Italy) 
for 10 min at room temperature in the dark, then stopped 
with 50 μl of 0.5 M H2SO4. A nine-point standard curve 
(concentration range 50 to 0.195 ng/ml) was obtained 
using recombinant, human His-tagged CD157 (rhCD157, 
R&D System, Milano, Italy). Absorbance read at 450 
nm was used to determine sCD157 concentration by 
comparison of means of the replicate measurements with 
the standard curve performed in each plate. The standard 
curve was generated by plotting the mean O.D. for each 
standard on the y-axis and the concentration on the x-axis 
and drawing a best fit curve through the points on the 
graph using a four parameter logistic (4-PL) curve fit. To 
validate the accuracy of our results, the intra-assay and 
inter-assay coefficient of variation (CV) were determined. 
Three effusion samples with low, middle and high levels 
of sCD157 were tested ten times on one plate (precision 
within an assay), or in three different plates, 6 replicates 
in each plate, (precision between assays). We obtained an 
intra- and inter-assay CV <9% and <7%, respectively (not 
shown).
Study participants
Pleural effusions (2 ml/each) were obtained from 
295 consecutive patients who underwent thoracentesis 
at the Division of Pathology, Thoracic Oncology and 
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Thoracic Surgery at San Luigi Gonzaga Hospital, Torino, 
Italy, between November 2012 and October 2016. The 
diagnosis of MPM was based on clinical signs, imaging 
data, cytological examination of pleural effusions and/or 
histology of pleural biopsies. Patients with MPM were 
enrolled before starting any therapeutic treatment. Fresh 
effusion samples were retrieved without anticoagulant, 
centrifuged for 10 min at 2,000 × g, and immediately 
stored at –80° C until use. All specimens were analysed 
by cytology and, when necessary for diagnosis, by 
immunohistochemistry of pleural biopsies taken during 
thoracoscopy. Effusions were considered as malignant 
based on a demonstration of malignant cells by cytology 
and/or by histology in biopsy specimens. Patients were 
defined as having non-malignant diseases when there were 
no signs of ongoing or previous tumor and a one year of 
follow-up did not show any clinical evidence of tumor. 
No information was available concerning exposure to 
asbestos, and no attempt was made to distinguish exudates 
from transudates. Metastatic pleural diseases correlated 
with advanced stage, while information of stage for MPM 
patients was not available for this study. All assays were 
performed on coded samples by technical staff unaware 
of patient’s diagnosis. The study was approved by the San 
Luigi Gonzaga Hospital Institutional Review Board and 
participants gave informed written consent. All studies 
on human subjects were carried out according to the 
Declaration of Helsinki. 
Immunohistochemistry
Sections (5 μm) from formalin-fixed MPM 
thoracoscopic biopsies were analysed for CD157 
expression using the RF3 anti-CD157 mAb (Space, 
Milano, Italy), as described [24]. CD157 expression was 
evaluated using a semi-quantitative histological score 
(H-score) calculated by summing the percentage of 
cells stained at each intensity level (0–100) in the whole 
section, multiplied by the weighted intensity (0, none; 1, 
weak; 2, moderate; 3, intense), generating for each tumor 
a score ranging from 0 to 300. An experienced pathologist, 
blind of the levels of sCD157 in effusions, evaluated all 
slides.
Statistical analysis
Unless otherwise indicated, results are expressed 
as mean value ± s.e.m. Comparison between groups were 
performed using the non-parametric Mann-Whitney U-test 
for independent samples, with adjustment for multiple 
comparisons using the Dunn’s method. sCD157 levels 
were shown as median and interquartile range (IQR: 25th 
and 75th percentiles). Means, SD, median, and range 
were used to describe the age of patients; other clinical 
and pathological characteristics of MPM patients were 
shown in terms of number of cases and grouped according 
to the median sCD157 concentration (<31.02 or ≥31.02 
ng/ml). The association between sCD157 concentration 
and clinical data was analysed using the χ2 test or Fisher 
exact test. The distribution of sCD157 values among the 
groups under study was evaluated by receiver operating 
characteristics (ROC) analysis, using the area under the 
ROC curve (AUC) as a measure of accuracy. AUC were 
reported with their 95% confidence intervals (95% CI). 
On the basis of the ROC analysis, the optimal sCD157 
cut-off point of discrimination between the study 
subgroups was determined using the Youden Index, which 
reflects the joint maximum values of sensitivity and 
specificity. Survival time was defined as time between 
pleural effusion withdrawal and date of death or date of 
last follow-up. Patients still alive at last follow-up were 
considered censored. Patients alive but not reaching at 
least median OS (11 months) were excluded from this 
analysis. The Kaplan-Meier method was used for survival 
estimation and the log-rank test was performed to compare 
differences in OS between groups. A P value < 0.05 was 
considered statistically significant. Statistical analyses 
were performed using GraphPad Prism 6.01 and SPSS 
statistics V.24.
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